Industry Background - In 2025, the food industry is influenced by various factors including policy, economy, social structure, and technology, showcasing unique development trends and consumption patterns [2][4] - The government prioritizes "boosting consumption" as a key task, aiming to transition the food industry from "recovery growth" to "high-quality development" [2][4] - The GDP growth for 2024 is projected at 5%, but the food industry's added value has been declining for four consecutive years, indicating structural supply-demand issues [2][4] - The aging population is accelerating, with those aged 65 and above accounting for 15.6% of the population, while urbanization has reached 67%, shifting consumer dietary preferences from "sufficient" to "quality" [2][4] Core Consumption Trends - Six core consumption trends are identified as new directions for industry development: 1. **Diverse Channel Innovations**: 84.2% of consumers are purchasing alternative products, with retailers optimizing supply chains to lower prices and enhance value [3] 2. **Precision Nutrition Products**: New products targeting different age groups, including senior nutrition and children's dietary needs, are emerging [3] 3. **Emotional Value Experiences**: Marketing strategies focus on sensory and situational engagement, enhancing consumer emotional experiences [3] 4. **Key Demographic Opportunities**: Brands are targeting family nutrition, with rapid growth in urban markets and services for overseas tourists [3] 5. **Smart Information Experiences**: AI is being integrated into product development and production, enhancing personalized nutrition services [3] 6. **Green Revolution in Food and Beverage**: Transparency in supply chains and innovations in green packaging are gaining traction, with over 70% of consumers concerned about "no additives" [3] Strategic Focus for 2025 - The food industry must focus on channel efficiency, precision nutrition, and emotional value, leveraging AI and green technologies to address the needs of the aging population and urban-rural integration [4][5] - The transition from scale expansion to value creation is essential for building a sustainable development ecosystem [4][5]

Financial Performance & Targets - Ginkgo achieved $205 million in annual run-rate cost savings from Q1 2024 to Q1 2025[13] - The company maintains a strong financial position with $517 million in cash, cash equivalents, and marketable securities[15] - Total Adjusted EBITDA improved from $(117) million in Q1 2024 to $(47) million in Q1 2025, a 59% increase[34] - Ginkgo is targeting Adjusted EBITDA breakeven by the end of 2026[11, 49] - The company aims for $250 million of annualized run-rate savings target by the end of Q3 2025[53] Revenue & Growth - Cell Engineering revenue increased by 37% year-over-year, reaching $38 million in Q1 2025[34] - This includes recognition of $75 million non-cash deferred revenue from BiomEdit[24] - Total revenue increased by 27% year-over-year, from $38 million to $48 million[34] - Biosecurity revenue remained stable at $10 million in Q1 2025 compared to Q1 2024[34] Biosecurity Expansion - Ginkgo's biosecurity segment has expanded its reach to 127 countries of origin of flights sampled, representing 65% of nations globally[33] - The biosecurity network includes 11 key international airports and 45 collection nodes cumulatively in 2025[33]

Fiscal 2025 2Q Financial Results M A Y 2 0 2 5 Agenda Welcome Angela Bitting SVP, Corporate Affairs 2 | TWIST BIOSCIENCE | PROPRIETARY Quarterly Highlights Emily Leproust Chief Executive Officer Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements ...

Core Insights - The 66th National Pharmaceutical Machinery Exposition successfully concluded on April 25, 2025, at Chongqing International Expo Center, organized by HAINAN JING-BO-XIN EXHIBITION CO., LTD. [1] - The exposition attracted 1,686 exhibitors from 24 countries and regions, showcasing over 10,000 products across an exhibition space of 180,000 square meters, with more than 60,000 visitors from 88 countries and regions [3]. Industry Overview - The exposition included a Malaysia-China procurement matchmaking session, facilitating one-on-one meetings between over 20 Chinese manufacturers and six Malaysian pharmaceutical companies [3]. - The organizing committee hosted three thematic forums and 93 technical exchange sessions, featuring keynote speeches from renowned experts and industry professionals [4]. - The Second CIPM Synthetic Biology and Biomanufacturing Industry Development Conference was a significant highlight, attracting over 1,000 professionals from various sectors including pharmaceuticals, food, cosmetics, and pesticides [4]. Historical Context - The China National Pharmaceutical Machinery Exposition has been held biannually since the 1990s and has been recognized as a key exhibition supported by China's Ministry of Commerce since 2004 [5]. - The event expanded in 2008 to include the China International Pharmaceutical Machinery Exposition (CIPM), covering production, processing, packaging, testing, and auxiliary equipment for various industries [5]. - Over the years, CIPM has evolved into a premier global event that integrates trade, technology exchange, and industry dialogue [5].

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

作为新质生产力的代表，合成生物学、生物制造以及生物产业，近些年，受到来自政产学研用金各 方广泛关注和重点支持，多地政府将合成生物制造产业写进工作报告。 科学家、企业家和投资家， 在产业发展中发挥着重要作用。 融行业智慧、共襄盛举 聚产业力量、擘画未来 第三届SynBio Suzhou中国合成生物学"科学家+企业家+投资家"大会 将于2025年8月1-2日在 苏州 国际博览中心 举办（同期举办 第七届CMC-China博览会 ）！ 扫码！锁定免费参会名额！ 话题将覆盖： 农业、食品与能源， 医美、医药、大健康 ， 合成生物技术、中试放大与商业化， 以 及 项目路演 等多个方面，诚邀莅临，共襄盛举！ 往期精彩： 圆满落幕！下一站去哪？2023中国（苏州）合成生物学创新峰会成功举办 大会主办丨 Synbio深波 会议时间 | 2025年8月1-2日 会议地点 | 中国·苏州·国际博览中心B馆 扫码！锁定免费参会名额！ 往期嘉宾 阵容 （按首字母排序，排名不分先后， 嘉宾单位或头衔为参加往期活动时信息，或有改变 ） 2023中国(苏州)合成生物学产业技术峰会圆满落幕 合成生物，聚势苏州：2024中国合成生物学"科学家 ...

Investment Rating - The report indicates a positive investment outlook for the techbio sector, highlighting its transformation into a major global asset class with significant growth potential driven by emerging VC managers [3][4]. Core Insights - The techbio sector has evolved from a niche segment to a major global asset class over the past two decades, with emerging VC managers playing a crucial role in this growth despite broader market challenges [3][4]. - A platform-first investment philosophy is prevalent, focusing on technologies applicable across multiple biological domains, which enhances risk distribution and portfolio diversification [3][6]. - High-growth investment frontiers are emerging, particularly in AI-powered drug discovery, synthetic and computational biology, and lab automation technologies, presenting substantial investment opportunities [3][8][9][10]. - The investor landscape is diversifying, with traditional tech VCs entering the biology space, specialist techbio investors gaining prominence, and corporate venture arms making strategic investments [3][11]. - Future trends suggest consolidation and validation, with specialized megafunds focusing on computational biology as AI-discovered therapeutics advance [3][4]. Summary by Sections Key Takeaways - The techbio sector has transformed significantly, with emerging VC managers driving growth [3]. - A platform-first investment philosophy is dominating the space, providing economic advantages [3][6]. - High-growth investment frontiers include AI-powered drug discovery and lab automation technologies [3][8][9][10]. - The investor landscape is diversifying with traditional and specialist investors [3][11]. - Future trends indicate consolidation and a focus on computational biology [3][4]. Techbio Investor Highlights - The techbio sector has grown into a major global asset class, with emerging VC managers playing a pivotal role [4]. - Techbio fund formation has shown resilience despite market challenges, with notable funds closing successfully [5]. - A platform-first approach is reshaping investment strategies, emphasizing foundational technologies [6][7]. High-Growth Investment Frontiers - AI-powered drug discovery platforms are leveraging machine learning for accelerated development [8]. - Investments in synthetic and computational biology are enabling precision biology innovations [9]. - Automation and bioinfrastructure investments are enhancing laboratory capabilities [10]. The Money Movers - Traditional tech VCs are increasingly investing in techbio, often launching dedicated funds [11][12]. - Notable investors like Andreessen Horowitz and Pear VC are actively participating in the techbio space [12][16]. The Specialists - Dedicated life sciences venture firms are emerging, focusing on techbio investments [19]. - Firms like Civilization Ventures and Foresite Capital are leading in specialized investments [20][23]. The Corporate Kingmakers - Corporate venture arms like Google Ventures and NVentures are driving innovation in techbio [30][35]. - These firms leverage their corporate ecosystems to identify high-potential investments [30]. The Emerging Managers - New entrants like Atria Ventures are reshaping the techbio investment landscape [39]. - These firms focus on early-stage opportunities at the intersection of AI and biology [39][40]. The Next Wave of Techbio Investment - Specialization and capital concentration are expected to accelerate in the coming years [45]. - Clinical validation of AI-discovered therapeutics will influence future funding allocations [49]. - Investments in precision medicine and pharma automation technologies are projected to surge [50][51].